Targeting systemic and gut microbial metabolism in ER+ breast cancer.
Trends Endocrinol Metab
; 35(4): 321-330, 2024 Apr.
Article
em En
| MEDLINE
| ID: mdl-38220576
ABSTRACT
Estrogen receptor-positive (ER+) breast tumors have a better overall prognosis than ER- tumors; however, there is a sustained risk of recurrence. Mounting evidence indicates that genetic and epigenetic changes associated with resistance impact critical signaling pathways governing cell metabolism. This review delves into recent literature concerning the metabolic pathways regulated in ER+ breast tumors by the availability of nutrients and endocrine therapies and summarizes research on how changes in systemic and gut microbial metabolism can affect ER activity and responsiveness to endocrine therapy. As targeting of metabolic pathways using dietary or pharmacological approaches enters the clinic, we provide an overview of the supporting literature and suggest future directions.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
/
Microbioma Gastrointestinal
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article